AUS
NZ
UK
CA
USA
IND
NOVONIX Limited, a leading battery materials and technology firm, has secured essential waivers from the ASX that permit the company to move forward with its Share Purchase Plan (SPP) without needing shareholder approval. This advancement allows NOVONIX to offer shares at a discounted rate consistent with its recent Institutional Placement terms.<\/p> <\/div>
Key Points<\/h3>
- Company and ticker: NOVONIX Limited (NVX)<\/li>
- Main update: ASX grants waivers for Share Purchase Plan implementation<\/li>
- Important figures: Offer Price set at $0.16 per share, reflecting a 31.2% discount to the 5-day VWAP<\/li>
- Next steps for investors: SPP results to be announced on or around 17 August 2026<\/li>
<\/ul>
<\/div>
ASX Waivers Facilitate Discounted Share Issuance<\/h2>
NOVONIX Limited has announced receipt of waivers from ASX Listing Rules 7.1 and 10.11, enabling the company to proceed with its Share Purchase Plan (SPP) without shareholder approval. This permits issuing new shares at an Offer Price of $0.16, which is notably below 80% of the 5-day volume weighted average price (VWAP) before the announcement.<\/p>
The waivers allow NOVONIX to offer shares under the SPP at an approximate 31.2% discount to the 5-day VWAP calculated through 15 June 2026. This approach aims to provide retail investors with the opportunity to participate in the capital raising on equal footing with institutional investors.<\/p>
Waiver Terms and Their Effects<\/h2>
The ASX waivers include conditions such as the SPP share issue price not being lower than the Institutional Placement price of $0.16 per share. Additionally, the total number of SPP shares must not exceed 30% of NOVONIX's fully paid ordinary shares on issue.<\/p>
These conditions are intended to ensure the capital raising is fair and efficient without significantly increasing dilution for existing shareholders. Participation in the SPP is voluntary, subject to application limits, with an expected overall dilution of approximately 2.17%.<\/p>
Strategic Purpose for Seeking Waivers<\/h2>
NOVONIX sought these waivers to align the SPP terms with those of the Institutional Placement, enabling eligible shareholders to purchase shares at the same discounted price. This strategy promotes fairness among all investors and accelerates the capital raising process.<\/p>
Without these waivers, NOVONIX would have encountered delays and higher costs due to the need for shareholder approval. The company noted that similar waivers have been granted to other ASX-listed companies in comparable circumstances.<\/p>
SPP Timeline<\/h2>
Following waiver approval, NOVONIX set the SPP timetable: the record date was 7:00 pm on 16 June 2026; the SPP opened and the booklet became available on 22 June 2026; and the SPP closes at 5:00 pm on 14 August 2026.<\/p>
The company expects to announce SPP results on or about 17 August 2026, allot shares on 19 August 2026, and commence trading of new shares on 20 August 2026, pending ASX confirmation.<\/p>
Impact on Capital Raising Strategy<\/h2>
These waivers represent a strategic step for NOVONIX to efficiently complete its capital raising. Allowing retail investors to join the SPP under the same terms as institutional investors aims to expand the shareholder base and secure funds to support growth initiatives.<\/p>
This move aligns with NOVONIX's broader plan to scale operations and increase manufacturing capacity to meet growing global demand for battery materials. The company is focused on establishing a robust North American supply chain critical to advancing U.S. energy independence.<\/p>
Market Response and Investor Outlook<\/h2>
The immediate effect on NOVONIX's share price was not evident from public information. Nonetheless, investors may interpret the waivers and SPP as positive steps toward enhancing shareholder value and supporting the company’s expansion goals.<\/p>
Investors should watch for the upcoming SPP results and the start of trading for new shares, which could offer further insight into market sentiment regarding the capital raise.<\/p>
NOVONIX's Dedication to Shareholder Fairness<\/h2>
By obtaining these waivers, NOVONIX underscores its commitment to equitable shareholder treatment. The SPP is structured to enable retail investors to participate on equal terms with institutional investors, reflecting a balanced capital raising approach.<\/p>
This focus on fairness is expected to boost investor confidence and support NOVONIX’s efforts to grow its market presence and operational capabilities.<\/p>
Outlook for NOVONIX<\/h2>
Looking forward, NOVONIX is set to continue expanding in the battery materials sector by leveraging proprietary technologies and increasing production capacity. Successful completion of the SPP will provide additional capital to pursue strategic objectives and capitalize on rising demand for lithium-ion battery materials.<\/p>
Investors will closely monitor NOVONIX’s progress in executing its growth strategy and the potential effects on financial performance and market positioning.<\/p>
ASX Waivers Facilitate Discounted Share Issuance<\/h2>
NOVONIX Limited has announced receipt of waivers from ASX Listing Rules 7.1 and 10.11, enabling the company to proceed with its Share Purchase Plan (SPP) without shareholder approval. This permits issuing new shares at an Offer Price of $0.16, which is notably below 80% of the 5-day volume weighted average price (VWAP) before the announcement.<\/p>
The waivers allow NOVONIX to offer shares under the SPP at an approximate 31.2% discount to the 5-day VWAP calculated through 15 June 2026. This approach aims to provide retail investors with the opportunity to participate in the capital raising on equal footing with institutional investors.<\/p>
Waiver Terms and Their Effects<\/h2>
The ASX waivers include conditions such as the SPP share issue price not being lower than the Institutional Placement price of $0.16 per share. Additionally, the total number of SPP shares must not exceed 30% of NOVONIX's fully paid ordinary shares on issue.<\/p>
These conditions are intended to ensure the capital raising is fair and efficient without significantly increasing dilution for existing shareholders. Participation in the SPP is voluntary, subject to application limits, with an expected overall dilution of approximately 2.17%.<\/p>
Strategic Purpose for Seeking Waivers<\/h2>
NOVONIX sought these waivers to align the SPP terms with those of the Institutional Placement, enabling eligible shareholders to purchase shares at the same discounted price. This strategy promotes fairness among all investors and accelerates the capital raising process.<\/p>
Without these waivers, NOVONIX would have encountered delays and higher costs due to the need for shareholder approval. The company noted that similar waivers have been granted to other ASX-listed companies in comparable circumstances.<\/p>
SPP Timeline<\/h2>
Following waiver approval, NOVONIX set the SPP timetable: the record date was 7:00 pm on 16 June 2026; the SPP opened and the booklet became available on 22 June 2026; and the SPP closes at 5:00 pm on 14 August 2026.<\/p>
The company expects to announce SPP results on or about 17 August 2026, allot shares on 19 August 2026, and commence trading of new shares on 20 August 2026, pending ASX confirmation.<\/p>
Impact on Capital Raising Strategy<\/h2>
These waivers represent a strategic step for NOVONIX to efficiently complete its capital raising. Allowing retail investors to join the SPP under the same terms as institutional investors aims to expand the shareholder base and secure funds to support growth initiatives.<\/p>
This move aligns with NOVONIX's broader plan to scale operations and increase manufacturing capacity to meet growing global demand for battery materials. The company is focused on establishing a robust North American supply chain critical to advancing U.S. energy independence.<\/p>
Market Response and Investor Outlook<\/h2>
The immediate effect on NOVONIX's share price was not evident from public information. Nonetheless, investors may interpret the waivers and SPP as positive steps toward enhancing shareholder value and supporting the company’s expansion goals.<\/p>
Investors should watch for the upcoming SPP results and the start of trading for new shares, which could offer further insight into market sentiment regarding the capital raise.<\/p>
NOVONIX's Dedication to Shareholder Fairness<\/h2>
By obtaining these waivers, NOVONIX underscores its commitment to equitable shareholder treatment. The SPP is structured to enable retail investors to participate on equal terms with institutional investors, reflecting a balanced capital raising approach.<\/p>
This focus on fairness is expected to boost investor confidence and support NOVONIX’s efforts to grow its market presence and operational capabilities.<\/p>
Outlook for NOVONIX<\/h2>
Looking forward, NOVONIX is set to continue expanding in the battery materials sector by leveraging proprietary technologies and increasing production capacity. Successful completion of the SPP will provide additional capital to pursue strategic objectives and capitalize on rising demand for lithium-ion battery materials.<\/p>
Investors will closely monitor NOVONIX’s progress in executing its growth strategy and the potential effects on financial performance and market positioning.<\/p>
